| Olivia Ann Keenan, DNP, APRN, FNP-BC | |
|
7825 Woodstone Ln, Lenexa, KS 66217-9622 | |
| (785) 640-8818 | |
| Not Available |
| Full Name | Olivia Ann Keenan |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 7825 Woodstone Ln, Lenexa, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073135430 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 53-78921-052 (Kansas) | Primary |
| 163WP0200X | Registered Nurse - Pediatrics | 13-111822-052 (Kansas) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Olivia Ann Keenan, DNP, APRN, FNP-BC 7825 Woodstone Ln, Lenexa, KS 66217-9622 Ph: (785) 640-8818 | Olivia Ann Keenan, DNP, APRN, FNP-BC 7825 Woodstone Ln, Lenexa, KS 66217-9622 Ph: (785) 640-8818 |
News Archive
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.
A new study shows that pancreatic cancer patients 65 or older who live at least five years after surgery have nearly as good a chance as anyone else to live another five years.
DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
Israel-based Elbit Medical Imaging on Monday said that FDA has approved software that aims to reduce treatment time for the uterine fibroid device ExAblate 2000, the AP/Forbes reports.
› Verified 7 days ago
Eileen Frances Frausto, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 9913 Sunset Dr, Lenexa, KS 66220 Phone: 913-308-5498 | |
Everett G. Bennett Iii, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11001 Hauser St, Lenexa, KS 66210 Phone: 913-353-4703 Fax: 949-543-2954 | |
Robert Otto, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 7721 Quivira Rd, Lenexa, KS 66216 Phone: 913-706-2508 Fax: 913-248-2808 | |
Mrs. Lillie Mae Dean, REG.NURSEPRACTIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10101 Renner Blvd, Lenexa, KS 66219 Phone: 913-577-1641 Fax: 913-859-6887 | |
Hailey Wank, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11150 Thompson Ave, Lenexa, KS 66219 Phone: 913-850-7500 Fax: 913-850-7579 | |
Jessica Michelle Croft, MSN, APRN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 15928 W 84th Ter, Lenexa, KS 66219 Phone: 913-653-3356 |